Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Microcytotoxicity and Serum Blocking Factors in Malignant Melanoma and Halo Nevus

Microcytotoxicity and Serum Blocking Factors in Malignant Melanoma and Halo Nevus Abstract Microcytotoxicity assays of patients with malignant melanoma and halo nevi were performed. No good correlation could be found between percent cell inhibition and histopathological level of melanoma or the clinical staging. The percent cell inhibition was usually an index of response to vaccinia virus immunotherapy. Actively regressing halo nevi showed high levels of percent cell inhibition, whereas inactive halo nevi had low levels of percent cell inhibition and blocking factor. Immunologic reactivity to melanoma cells may be a common feature of melanoma and halo nevus. References 1. Morton DL, Malmgren RA, Holmes EC, et al: Demonstration of antibodies against human malignant melanoma by immunofluorescence . Surgery 64:233-240, 1968. 2. Lewis MG, Ikonopisov RL, Nairn RC, et al: Tumor specific antibodies in human malignant melanoma and their relationship to the extent of the disease . Br Med J 3:447-452, 1969.Crossref 3. Hellström I, Hellström KE, Pierce GE, et al: Cellular and humoral immunity to different types of human neoplasms . Nature 220:1352-1354, 1968.Crossref 4. Copeman PWM, Lewis MG, Phillips TM, et al: Immunological associations of the halo nevus with cutaneous malignant melanoma . Br J Dermatol 88:127-137, 1973.Crossref 5. Hellström I, Hellström KE: Colony inhibition and cytotoxicity assays , in Bloom BP, Glade PR (eds): In Vitro Methods in Cell-Mediated Immunity . New York, Academic Press Inc, 1971, pp 409-414. 6. Böyum A: Separation of leucocytes from blood and bone marrow . Scand J Clin Lab Invest 21( (suppl 97) ):31-50, 1968.Crossref 7. Lewis MG: Possible immunological factors in human malignant melanoma in Uganda . Lancet 2:921-922, 1967.Crossref 8. Hellström I, Hellström KE, Sjogren HD, et al: Demonstration of cell-mediated immunity to human neoplasms of various histological types . Int J Cancer 7:1-16, 1971.Crossref 9. Hellström KE, Hellström I: Immunity to neuroblastoma and melanomas . Annu Rev Med 23:19-38, 1972.Crossref 10. Hellström I, Hellström KE: Some recent studies of cellular immunity to human melanomas . Fed Proc 32:156-159, 1973. 11. Byrne M, Heppner G, Stolbach L, et al: Tumor immunity in melanoma patients as assessed by colony report . Natl Cancer Inst Monogr 37:3-8, 1973. 12. Takasugi M, Terasaki P: Reactivity of lymphocytes from normal persons on cultured tumor cells . Cancer Res 33:2898-2902, 1973. 13. Clark WH Jr, From L, Bernardina EA, et al: The histogenesis and biologic behavior of primary human malignant melanomas of the skin . Cancer Res 29:705-727, 1969. 14. McGovern VJ: The classification of melanoma and its relationship with prognosis . Pathology 2:85-98, 1970.Crossref 15. Huvos AG, Mike V, Donnellan MJ, et al: Prognostic factors in cutaneous melanoma of the head and neck . Am J Pathol 71:33-45, 1973. 16. De Vries JE, Rumke P: Immunological studies in melanoma patients treated with BCG . Br J Cancer 28:97-102, 1973. 17. Burdick KH: Malignant melanoma treated with vaccinia injections , abstracted. Arch Dermatol 82:438-439, 1960. 18. Burdick KH, Hawk WA: Vitiligo in a case of vaccinia virus-treated melanoma . Cancer 17:708-712, 1964.Crossref 19. Roenigk HH Jr., Deodhar S, St. Jacques R, et al: Immunotherapy of malignant melanoma with vaccinia virus . Arch Dermatol 109:668-673, 1974.Crossref 20. Price FB, Hewlett JS, Deodhar SD, et al: The therapy of malignant melanoma with transfer factor: A preliminary report . Cleve Clin Q 41:1-4, 1974. 21. Sutton RL: Unusual variety of vitiligo (leukoderma acquisitum centrifugum) . J Cutan Dis 34:797-800, 1916. 22. Kopf AW, Morrill SD, Silberberg I: Broad spectrum of leukoderma acquisitum centrifugum . Arch Dermatol 92:14-35, 1965.Crossref 23. Wayte DM, Helwig EB: Halo nevi. Cancer 22:69-90, 1968.Crossref 24. Shapiro L, Kopf AW: Leukoderma acquisitum centrifugum: An unusual case . Arch Dermatol 92:64-68, 1965.Crossref 25. Sumner WC: Spontaneous regression of melanoma . Cancer 6:1040-1043, 1953.Crossref 26. Das Gupta T, Bowden L, Berg JW: Malignant melanoma of unknown primary origin . Surg Gynecol Obstet 117:341-345, 1963. 27. Matsuzawa T, Watanabe M, Knodo R: Case of leukoderma in x-rayed portion of patient with melanosarcoma . Shinshu Med J 2:254-258, 1953. 28. Stehlin JS, in discussion, Spoor HJ: Effect of topical hormones and other dermatologicals on melanin pigmentation . Ann NY Acad Sci 100:57, 1963. 29. Ito M, Yoshida Y: Malignant melanoma . Tohoku J Exp Med 55( (suppl 1) ):60-71, 1952.Crossref 30. Rohdenburg GL: Spontaneous recession of multiple pigmented moles . Arch Pathol 4:528-529, 1927. 31. Stegmaier OC: Natural regression of melanocytic nevus . J Invest Dermatol 32:413-420, 1959.Crossref 32. Stegmaier OC, et al: Multiple halo nevi. Arch Dermatol 99:180-189, 1969.Crossref 33. Epstein WL, Sagebeil R, Spitler L, et al: Halo nevi and melanoma . JAMA 225:373-377, 1973.Crossref 34. Lewis MG, Copeman PWN: Halo nevus: A frustrated malignant melanoma? Br Med J 2:47-48, 1972.Crossref 35. Jacobs JB, Edelstein LM, Synder LM: Halo nevus: A fine structural study of a host rejection phenomenon . Read before the 57th annual meeting of the Federation of American Societies for Experimental Biology , Atlantic City, 1973. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Archives of Dermatology American Medical Association

Microcytotoxicity and Serum Blocking Factors in Malignant Melanoma and Halo Nevus

Loading next page...
 
/lp/american-medical-association/microcytotoxicity-and-serum-blocking-factors-in-malignant-melanoma-and-p7VmkSv8D9
Publisher
American Medical Association
Copyright
Copyright © 1975 American Medical Association. All Rights Reserved.
ISSN
0003-987X
eISSN
1538-3652
DOI
10.1001/archderm.1975.01630180048003
Publisher site
See Article on Publisher Site

Abstract

Abstract Microcytotoxicity assays of patients with malignant melanoma and halo nevi were performed. No good correlation could be found between percent cell inhibition and histopathological level of melanoma or the clinical staging. The percent cell inhibition was usually an index of response to vaccinia virus immunotherapy. Actively regressing halo nevi showed high levels of percent cell inhibition, whereas inactive halo nevi had low levels of percent cell inhibition and blocking factor. Immunologic reactivity to melanoma cells may be a common feature of melanoma and halo nevus. References 1. Morton DL, Malmgren RA, Holmes EC, et al: Demonstration of antibodies against human malignant melanoma by immunofluorescence . Surgery 64:233-240, 1968. 2. Lewis MG, Ikonopisov RL, Nairn RC, et al: Tumor specific antibodies in human malignant melanoma and their relationship to the extent of the disease . Br Med J 3:447-452, 1969.Crossref 3. Hellström I, Hellström KE, Pierce GE, et al: Cellular and humoral immunity to different types of human neoplasms . Nature 220:1352-1354, 1968.Crossref 4. Copeman PWM, Lewis MG, Phillips TM, et al: Immunological associations of the halo nevus with cutaneous malignant melanoma . Br J Dermatol 88:127-137, 1973.Crossref 5. Hellström I, Hellström KE: Colony inhibition and cytotoxicity assays , in Bloom BP, Glade PR (eds): In Vitro Methods in Cell-Mediated Immunity . New York, Academic Press Inc, 1971, pp 409-414. 6. Böyum A: Separation of leucocytes from blood and bone marrow . Scand J Clin Lab Invest 21( (suppl 97) ):31-50, 1968.Crossref 7. Lewis MG: Possible immunological factors in human malignant melanoma in Uganda . Lancet 2:921-922, 1967.Crossref 8. Hellström I, Hellström KE, Sjogren HD, et al: Demonstration of cell-mediated immunity to human neoplasms of various histological types . Int J Cancer 7:1-16, 1971.Crossref 9. Hellström KE, Hellström I: Immunity to neuroblastoma and melanomas . Annu Rev Med 23:19-38, 1972.Crossref 10. Hellström I, Hellström KE: Some recent studies of cellular immunity to human melanomas . Fed Proc 32:156-159, 1973. 11. Byrne M, Heppner G, Stolbach L, et al: Tumor immunity in melanoma patients as assessed by colony report . Natl Cancer Inst Monogr 37:3-8, 1973. 12. Takasugi M, Terasaki P: Reactivity of lymphocytes from normal persons on cultured tumor cells . Cancer Res 33:2898-2902, 1973. 13. Clark WH Jr, From L, Bernardina EA, et al: The histogenesis and biologic behavior of primary human malignant melanomas of the skin . Cancer Res 29:705-727, 1969. 14. McGovern VJ: The classification of melanoma and its relationship with prognosis . Pathology 2:85-98, 1970.Crossref 15. Huvos AG, Mike V, Donnellan MJ, et al: Prognostic factors in cutaneous melanoma of the head and neck . Am J Pathol 71:33-45, 1973. 16. De Vries JE, Rumke P: Immunological studies in melanoma patients treated with BCG . Br J Cancer 28:97-102, 1973. 17. Burdick KH: Malignant melanoma treated with vaccinia injections , abstracted. Arch Dermatol 82:438-439, 1960. 18. Burdick KH, Hawk WA: Vitiligo in a case of vaccinia virus-treated melanoma . Cancer 17:708-712, 1964.Crossref 19. Roenigk HH Jr., Deodhar S, St. Jacques R, et al: Immunotherapy of malignant melanoma with vaccinia virus . Arch Dermatol 109:668-673, 1974.Crossref 20. Price FB, Hewlett JS, Deodhar SD, et al: The therapy of malignant melanoma with transfer factor: A preliminary report . Cleve Clin Q 41:1-4, 1974. 21. Sutton RL: Unusual variety of vitiligo (leukoderma acquisitum centrifugum) . J Cutan Dis 34:797-800, 1916. 22. Kopf AW, Morrill SD, Silberberg I: Broad spectrum of leukoderma acquisitum centrifugum . Arch Dermatol 92:14-35, 1965.Crossref 23. Wayte DM, Helwig EB: Halo nevi. Cancer 22:69-90, 1968.Crossref 24. Shapiro L, Kopf AW: Leukoderma acquisitum centrifugum: An unusual case . Arch Dermatol 92:64-68, 1965.Crossref 25. Sumner WC: Spontaneous regression of melanoma . Cancer 6:1040-1043, 1953.Crossref 26. Das Gupta T, Bowden L, Berg JW: Malignant melanoma of unknown primary origin . Surg Gynecol Obstet 117:341-345, 1963. 27. Matsuzawa T, Watanabe M, Knodo R: Case of leukoderma in x-rayed portion of patient with melanosarcoma . Shinshu Med J 2:254-258, 1953. 28. Stehlin JS, in discussion, Spoor HJ: Effect of topical hormones and other dermatologicals on melanin pigmentation . Ann NY Acad Sci 100:57, 1963. 29. Ito M, Yoshida Y: Malignant melanoma . Tohoku J Exp Med 55( (suppl 1) ):60-71, 1952.Crossref 30. Rohdenburg GL: Spontaneous recession of multiple pigmented moles . Arch Pathol 4:528-529, 1927. 31. Stegmaier OC: Natural regression of melanocytic nevus . J Invest Dermatol 32:413-420, 1959.Crossref 32. Stegmaier OC, et al: Multiple halo nevi. Arch Dermatol 99:180-189, 1969.Crossref 33. Epstein WL, Sagebeil R, Spitler L, et al: Halo nevi and melanoma . JAMA 225:373-377, 1973.Crossref 34. Lewis MG, Copeman PWN: Halo nevus: A frustrated malignant melanoma? Br Med J 2:47-48, 1972.Crossref 35. Jacobs JB, Edelstein LM, Synder LM: Halo nevus: A fine structural study of a host rejection phenomenon . Read before the 57th annual meeting of the Federation of American Societies for Experimental Biology , Atlantic City, 1973.

Journal

Archives of DermatologyAmerican Medical Association

Published: Jun 1, 1975

References